A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2

Trial Profile

A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Copanlisib (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS-2
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 31 Oct 2019 to 7 May 2018.
    • 07 Jun 2017 Planned primary completion date changed from 31 Mar 2019 to 7 May 2018.
    • 27 Apr 2017 The study has been suspended in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top